Silverback Raises $78.5m To Test Localized Therapy Delivered Systemically In Patients

The company will initiate a clinical trial this year for lead ADC candidate SBT6050, which links a HER2-targeting antibody to a TLR8 agonist to activate myeloid cells in the tumor and spur an immune response.